Sign In
Buy IGC
$0.300
+0.0100 (+3.45%)
At Close: Jun 03, 2026
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends
09:00am, Tuesday, 25'th Nov 2025
POTOMAC, MD / ACCESS Newswire / November 25, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innova
Company Accelerates Phase 2 Alzheimer's Program and Gains National Institute on Aging (NIA) Recognition for AI Leadership POTOMAC, MARYLAND / ACCESS Newswire / November 17, 2025 / IGC Pharma, Inc. (NY
IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates
06:36pm, Friday, 14'th Nov 2025
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.02 per share a year ago.
USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders
09:00am, Thursday, 13'th Nov 2025
POTOMAC, MARYLAND / ACCESS Newswire / November 13, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging Artificial Int
IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025
09:00am, Monday, 10'th Nov 2025
POTOMAC, MARYLAND / ACCESS Newswire / November 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop
IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline
08:52am, Monday, 03'rd Nov 2025
POTOMAC, MARYLAND / ACCESS Newswire / November 3, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop i
All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy
01:01pm, Friday, 24'th Oct 2025
IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for Oct. 24
11:01am, Friday, 24'th Oct 2025
ASM, IGC and RY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 24, 2025.
New Strong Buy Stocks for Oct. 24: IGC, ASM and More
06:21am, Friday, 24'th Oct 2025
IGC, SCRYY, RY, UVE and ASM have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 24, 2025.
IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"
09:00am, Wednesday, 22'nd Oct 2025
POTOMAC, MD / ACCESS Newswire / October 22, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovat
POTOMAC, MD / ACCESS Newswire / October 14, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovat
IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders
07:50pm, Friday, 10'th Oct 2025
POTOMAC, MARYLAND / ACCESS Newswire / October 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop i
IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease
09:00am, Tuesday, 07'th Oct 2025
IGC-1C Targets Tau Protein's Liquid-Liquid Phase Separation (LLPS), Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed POTOMAC, MD / ACCESS Newswire / October 7, 2025 / IGC P
IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial
09:00am, Monday, 29'th Sep 2025
POTOMAC, MD / ACCESS Newswire / September 29, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the addition of a new clinical trial site to its ongoing Phase 2 study evaluating IGC-AD1, an
IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology
09:00am, Wednesday, 24'th Sep 2025
POTOMAC, MD / ACCESS Newswire / September 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced preclinical findings on TGR-63, the Company's investigational small-molecule candidate for Alz
